Literature DB >> 35895583

Serologic and Cytokine Profiles of Children with Concurrent Cerebral Malaria and Severe Malarial Anemia Are Distinct from Other Subtypes of Severe Malaria.

Rafal S Sobota1,2, Abby R Goron1, Andrea A Berry1, Jason A Bailey1, Drissa Coulibaly3, Matthew Adams1, Abdoulaye K Kone3, Bourema Kouriba3, Ogobara K Doumbo3, Marcelo B Sztein1, Philip L Felgner4, Christopher V Plowe1, Kirsten E Lyke1, Mahamadou A Thera3, Mark A Travassos1.   

Abstract

We used a protein microarray featuring Plasmodium falciparum field variants of a merozoite surface antigen to examine malaria exposure in Malian children with different severe malaria syndromes. Unlike children with cerebral malaria alone or severe malarial anemia alone, those with concurrent cerebral malaria and severe malarial anemia had serologic responses demonstrating a broader prior parasite exposure pattern than matched controls with uncomplicated disease. Comparison of levels of malaria-related cytokines revealed that children with the concurrent phenotype had elevated levels of interleukin (IL)-6, IL-8, and IL-10. Our results suggest that the pathophysiology of this severe subtype is unique and merits further investigation.

Entities:  

Year:  2022        PMID: 35895583      PMCID: PMC9393435          DOI: 10.4269/ajtmh.22-0135

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  15 in total

1.  Seroreactivity to Plasmodium falciparum erythrocyte membrane protein 1 intracellular domain in malaria-exposed children and adults.

Authors:  Mark A Travassos; Amadou Niangaly; Jason A Bailey; Amed Ouattara; Drissa Coulibaly; Matthew B Laurens; Jozelyn Pablo; Algis Jasinskas; Rie Nakajima-Sasaki; Andrea A Berry; Shannon Takala-Harrison; Bourema Kouriba; J Alexandra Rowe; Kirsten E Lyke; Ogobara K Doumbo; Mahamadou A Thera; Philip L Felgner; Christopher V Plowe
Journal:  J Infect Dis       Date:  2013-07-30       Impact factor: 5.226

2.  A molecular marker for chloroquine-resistant falciparum malaria.

Authors:  A Djimdé; O K Doumbo; J F Cortese; K Kayentao; S Doumbo; Y Diourté; D Coulibaly; A Dicko; X Z Su; T Nomura; D A Fidock; T E Wellems; C V Plowe
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

3.  Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls.

Authors:  K E Lyke; R Burges; Y Cissoko; L Sangare; M Dao; I Diarra; A Kone; R Harley; C V Plowe; O K Doumbo; M B Sztein
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali.

Authors:  Kirsten E Lyke; Alassane Dicko; Abdoulaye Kone; Drissa Coulibaly; Ando Guindo; Yacouba Cissoko; Karim Traoré; Christopher V Plowe; Ogobara K Doumbo
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

Review 5.  Putative pathophysiological interactions of cytokines and phagocytic cells in severe human falciparum malaria.

Authors:  A D Urquhart
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

6.  Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity.

Authors:  Jo-Anne Chan; Katherine B Howell; Linda Reiling; Ricardo Ataide; Claire L Mackintosh; Freya J I Fowkes; Michaela Petter; Joanne M Chesson; Christine Langer; George M Warimwe; Michael F Duffy; Stephen J Rogerson; Peter C Bull; Alan F Cowman; Kevin Marsh; James G Beeson
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

7.  Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets.

Authors:  Mark A Travassos; Amadou Niangaly; Jason A Bailey; Amed Ouattara; Drissa Coulibaly; Kirsten E Lyke; Matthew B Laurens; Jozelyn Pablo; Algis Jasinskas; Rie Nakajima; Andrea A Berry; Matthew Adams; Christopher G Jacob; Andrew Pike; Shannon Takala-Harrison; Li Liang; Bourema Kouriba; Abdoulaye K Kone; J Alexandra Rowe; JoAnn Moulds; Dapa A Diallo; Ogobara K Doumbo; Mahamadou A Thera; Philip L Felgner; Christopher V Plowe
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

8.  Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag.

Authors:  Emily M Stucke; Amadou Niangaly; Andrea A Berry; Jason A Bailey; Drissa Coulibaly; Amed Ouattara; Kirsten E Lyke; Matthew B Laurens; Antoine Dara; Matthew Adams; Jozelyn Pablo; Algis Jasinskas; Rie Nakajima; Albert E Zhou; Sonia Agrawal; DeAnna J Friedman-Klabanoff; Shannon Takala-Harrison; Bourema Kouriba; Abdoulaye K Kone; J Alexandra Rowe; Ogobara K Doumbo; Philip L Felgner; Mahamadou A Thera; Christopher V Plowe; Mark A Travassos
Journal:  Malar J       Date:  2019-08-13       Impact factor: 2.979

9.  Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.

Authors:  Jason A Bailey; Andrea A Berry; Mark A Travassos; Amed Ouattara; Sarah Boudova; Emmanuel Y Dotsey; Andrew Pike; Christopher G Jacob; Matthew Adams; John C Tan; Ryan M Bannen; Jigar J Patel; Jozelyn Pablo; Rie Nakajima; Algis Jasinskas; Sheetij Dutta; Shannon Takala-Harrison; Kirsten E Lyke; Matthew B Laurens; Amadou Niangaly; Drissa Coulibaly; Bourema Kouriba; Ogobara K Doumbo; Mahamadou A Thera; Philip L Felgner; Christopher V Plowe
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

10.  Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation.

Authors:  Noah T Ventimiglia; Emily M Stucke; Drissa Coulibaly; Andrea A Berry; Kirsten E Lyke; Matthew B Laurens; Jason A Bailey; Matthew Adams; Amadou Niangaly; Abdoulaye K Kone; Shannon Takala-Harrison; Bourema Kouriba; Ogobara K Doumbo; Phillip L Felgner; Christopher V Plowe; Mahamadou A Thera; Mark A Travassos
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.